Sanofi’s Allegra dominates OTC·ETC drug market

By Nho, Byung Chul | translator Alice Kang

22.06.24 06:20:00

가나다라 0

Fexofenadine 120mg dose accounts for over 60% of the OTC market

Original drug shows strength in the ETC market as well… its generic Fexonadine make ₩1 billion externally

The market for OTCs and ETCs of the antihistamine ingredient fexofenadine hydrochloride has been showing stagnant performance with its sales making a rectangle pattern for several years now.

The market is virtually monopolized by the original drug, Sanofi’s Allegra Tab., with the total market estimated to be in the ₩8 billion range.

One aspect to note is that the high-dose 120mg Allegra Tab. is listed for reimbursement as an OTC, and the other 180·60·30mg strengths of Allegra are distributed and prescribed as ETCs in Korea. This is analyzed as a strategic decision made by the company in consideration of the clinical protocol, design, and efficacy of its drug.

Alle

Nho, Byung Chul(sasiman@dailypharm.com)

If you want to see the full article, please JOIN US (click)